Prenatal was BillionToOne’s largest product and service line in fiscal 2025, bringing in $277.11M of $305.11M (91%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Prenatal | $68.80M | $145.90M | $277.11M |
| Oncology | — | $2.94M | $24.95M |
| Clinical Trial Support & Other Services | $2.93M | $3.74M | $3.05M |
| Total | $71.73M | $152.58M | $305.11M |
BillionToOne brought in $305.11M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 100.0% from $152.58M in fiscal 2024. Prenatal was the largest at $277.11M (90.8%), ahead of Oncology at $24.95M (8.2%) and Clinical Trial Support & Other Services at $3.05M (1.0%).
Compared with fiscal 2024, Oncology grew 747.6% to $24.95M and Prenatal grew 89.9% to $277.11M.
BillionToOne began breaking out Oncology in fiscal 2024, when it brought in $2.94M.
BillionToOne (BLLN) reports its revenue by product and service. In fiscal 2025, Prenatal was its largest product and service line, bringing in $277.11M (90.8% of the total), followed by Oncology at $24.95M (8.2%).
Prenatal was BillionToOne's largest product and service line in fiscal 2025, bringing in $277.11M, or 90.8% of the $305.11M total across its three product and service lines.
Oncology grew faster than Prenatal in fiscal 2025, up 747.6% from $2.94M to $24.95M. Prenatal grew 89.9% to $277.11M.
Every figure comes from BillionToOne's annual financial filings, as reported. Each line keeps the name BillionToOne gives it, and years follow its fiscal calendar.
BillionToOne's revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.